- Effective April 1, 2026, Takeda will implement changes to its executive leadership and organizational structure.
- The International Business Unit will oversee all markets outside the U.S., led by Giles Platford.
- A new Strategy & Portfolio Development group will be established to align therapeutic and corporate strategies.
- The Transformation Office, led by Lauren Duprey, will focus on company-wide transformation, including AI initiatives.
Organizational Changes
Effective April 1, 2026, Takeda will implement significant changes to its executive leadership team and organizational structure. These changes aim to enhance growth and speed in response to a complex market environment.
New Business Units
The International Business Unit (IBU) will oversee all markets outside the U.S., with Giles Platford as its leader. The Japan Pharma Business Unit (JPBU) will align with IBU for execution and financial planning. A new Strategy & Portfolio Development (SPD) group will be established to integrate therapeutic and corporate strategies, portfolio decision-making, and business development.
Leadership Roles
Lauren Duprey will lead the newly formed Transformation Office, focusing on company-wide transformation, including AI initiatives. Elaine Shannon will head Global Supply & Quality, while Awny Farajallah will continue to lead Global Medical, now elevated to an executive team function. Natalie Furney will lead Global Legal, Ethics & Compliance.
Recruitment Efforts
Takeda is actively recruiting for several key positions, including a new president for the Plasma-Derived Therapies Business Unit, a strategy and portfolio development officer, a chief human resources officer, and a head of Global Communications & Governance.
